Published in Int J Cancer on June 30, 2014
Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci U S A (2014) 1.36
Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma. Clin Cancer Res (2015) 0.88
PI3K isoform-selective inhibitors: next-generation targeted cancer therapies. Acta Pharmacol Sin (2015) 0.84
Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies. Stem Cells Int (2016) 0.81
Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas. PLoS One (2015) 0.79
Preclinical mouse models of osteosarcoma. Bonekey Rep (2015) 0.77
PI3K p110β isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition. J Exp Clin Cancer Res (2016) 0.77
Long noncoding RNAs in the progression, metastasis, and prognosis of osteosarcoma. Cell Death Dis (2016) 0.77
Targeting protein kinases to reverse multidrug resistance in sarcoma. Cancer Treat Rev (2015) 0.75
Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers. Oncotarget (2016) 0.75
IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev (2004) 2.72
The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev (2004) 2.35
Mechanisms of bone repair and regeneration. Trends Mol Med (2009) 1.61
Current therapeutic strategies and novel approaches in osteosarcoma. Cancers (Basel) (2013) 1.42
Opposite Effects of Soluble Factors Secreted by Adipose Tissue on Proliferating and Quiescent Osteosarcoma Cells. Plast Reconstr Surg (2016) 1.40
Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol (2003) 1.38
Useful side handle for holding needle during ultrasound-guided regional anesthesia. Reg Anesth Pain Med (2009) 1.38
Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer (2005) 1.30
Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling. Stem Cells (2012) 1.29
Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res (2007) 1.26
Recent advances in TGF-beta effects on chondrocyte metabolism. Potential therapeutic roles of TGF-beta in cartilage disorders. Cytokine Growth Factor Rev (2002) 1.24
Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma. Cancer Res (2011) 1.24
Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies. Expert Rev Anticancer Ther (2007) 1.23
Bisphosphonates: new therapeutic agents for the treatment of bone tumors. Trends Mol Med (2004) 1.19
Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. Cancer Res (2010) 1.12
Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis. J Pathol (2010) 1.11
Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. Cancer Res (2010) 1.10
Proteoglycans: key partners in bone cell biology. Bioessays (2007) 1.07
Concise review: embryonic stem cells: a new tool to study osteoblast and osteoclast differentiation. Stem Cells (2006) 1.07
FGFR2 signaling underlies p63 oncogenic function in squamous cell carcinoma. J Clin Invest (2013) 1.07
Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival. Int J Cancer (2006) 1.04
OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation. Bone (2006) 1.02
Osteoprotegerin: multiple partners for multiple functions. Cytokine Growth Factor Rev (2013) 1.02
Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma. Cancer Res (2009) 1.01
Safety concern between autologous fat graft, mesenchymal stem cell and osteosarcoma recurrence. PLoS One (2010) 1.01
Mesenchymal stem cells induce a weak immune response in the rat striatum after allo or xenotransplantation. J Cell Mol Med (2009) 1.00
Pericyte-like progenitors show high immaturity and engraftment potential as compared with mesenchymal stem cells. PLoS One (2012) 0.98
Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin M in osteosarcoma cells require PKCdelta and STAT3. J Bone Miner Res (2004) 0.98
Oxytocin reverses ovariectomy-induced osteopenia and body fat gain. Endocrinology (2014) 0.96
Autophagy in osteoblasts is involved in mineralization and bone homeostasis. Autophagy (2014) 0.96
Carotid and femoral atherosclerotic plaques show different morphology. Atherosclerosis (2011) 0.96
Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells. Oncol Rep (2007) 0.96
Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival. Clin Cancer Res (2010) 0.96
Expression and regulation of the Msx1 natural antisense transcript during development. Nucleic Acids Res (2005) 0.95
RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. Int J Oncol (2006) 0.95
A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis. Arthritis Res Ther (2009) 0.94
Feedback control of p53 translation by REDD1 and mTORC1 limits the p53-dependent DNA damage response. Mol Cell Biol (2011) 0.94
Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment. Int J Cancer (2014) 0.94
Mesenchymal stem cell transplantation and DMEM administration in a 3NP rat model of Huntington's disease: morphological and behavioral outcomes. Behav Brain Res (2010) 0.93
Transformation of human bronchial epithelial cells alters responsiveness to inflammatory cytokines. BMC Cancer (2005) 0.93
Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis. Joint Bone Spine (2010) 0.93
Targeting the EWSR1-FLI1 oncogene-induced protein kinase PKC-β abolishes ewing sarcoma growth. Cancer Res (2012) 0.92
Killer dendritic cells link innate and adaptive immunity against established osteosarcoma in rats. Cancer Res (2008) 0.91
First preclinical imaging of primary cartilage neoplasm and its local recurrence using 99mTc-NTP 15-5 radiotracer. J Nucl Med (2009) 0.90
Differentiation of osteoblasts from mouse embryonic stem cells without generation of embryoid body. In Vitro Cell Dev Biol Anim (2007) 0.90
Mifamurtide for the treatment of nonmetastatic osteosarcoma. Expert Opin Pharmacother (2011) 0.89
Enamel protein regulation and dental and periodontal physiopathology in MSX2 mutant mice. Am J Pathol (2010) 0.89
Proteoglycans on bone tumor development. Drug Discov Today (2010) 0.89
mTOR inhibitors (rapamycin and its derivatives) and nitrogen containing bisphosphonates: bi-functional compounds for the treatment of bone tumours. Curr Med Chem (2007) 0.89
Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma. Mol Cancer Ther (2008) 0.89
Distinct roles of Bcl-2 and Bcl-Xl in the apoptosis of human bone marrow mesenchymal stem cells during differentiation. PLoS One (2011) 0.88
TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment. Am J Cancer Res (2011) 0.88
RANKL/RANK/OPG: key therapeutic target in bone oncology. Curr Drug Discov Technol (2008) 0.87
Osteosarcoma: current status of immunotherapy and future trends (Review). Oncol Rep (2006) 0.87
Molecular alterations associated with osteosarcoma development. Sarcoma (2012) 0.86
Factor VIII-von Willebrand factor complex inhibits osteoclastogenesis and controls cell survival. J Biol Chem (2009) 0.86
Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models. J Bone Miner Res (2011) 0.86
Glial fibrillary acidic protein (GFAP)-positive radial-like cells are present in the vicinity of proliferative progenitors in the nucleus tractus solitarius of adult rat. J Comp Neurol (2007) 0.86